Adderall blends four amphetamine salts, and the dose changes everything
At prescribed doses, the ADHD drug Adderall sharpens focus, speeds reactions and fends off fatigue. Push far beyond those doses and the same chemistry can scramble thinking, trigger panic or psychosis, and carry a serious risk of dependence. In 2023 it filled more than 32 million American prescriptions, fifteenth among all medicines.
Adderall combines four amphetamine salts, supplying two mirror-image forms of the molecule. Dextroamphetamine is the stronger stimulant of the brain; levoamphetamine has slightly greater effects on the heart and body and lingers longer. Both boost the activity of dopamine and norepinephrine, partly by acting on a receptor called TAAR1 and on the transporter that packs neurotransmitters into storage vesicles. Chemically, amphetamine closely resembles trace amines the body makes itself, such as phenethylamine.
It is approved for ADHD and narcolepsy. Models of ADHD link the condition to weak dopamine and norepinephrine signalling in circuits reaching the prefrontal cortex, and roughly 80 per cent of people taking stimulants see symptoms improve. Trials running two years support long-term safety and effectiveness, and imaging reviews suggest treatment reduces some structural and functional brain differences seen in ADHD. Narcolepsy type 1 stems from the loss of about 70,000 orexin-producing neurons; amphetamine helps by raising wake-promoting signals, though sleep specialists rate it a third-line option backed by low-quality evidence.
The extended-release capsule is a piece of engineering. Half its beads release at once and the rest wait for a coating to dissolve, mimicking two immediate-release doses four hours apart and covering up to 12 hours. A related triple-bead product, Mydayis, stretches to 16 hours.
In healthy adults, a 2015 meta-analysis found low doses give modest but clear gains in working memory, inhibitory control and some attention, which helps explain why an estimated 5 to 35 per cent of college students report using diverted stimulants, mostly to study. A 2025 to 2026 study among low-income people who use drugs found some taking Ritalin or Adderall to counter oversedation from powerful opioids; those combining them were more likely to say they wanted help to stop, though the difference was not statistically significant.
Source: Adderall
